Verona Pharma
VRNA
VRNA was delisted on the 6th of October, 2025.
42 hedge funds and large institutions have $248M invested in Verona Pharma in 2021 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 6 increasing their positions, 8 reducing their positions, and 7 closing their positions.
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
29% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 7
22% more capital invested
Capital invested by funds: $203M → $248M (+$45.3M)
5% more funds holding
Funds holding: 40 → 42 (+2)
0.01% less ownership
Funds ownership: 7.71% → 7.69% (-0.01%)
25% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 8
97% less call options, than puts
Call options by funds: $12K | Put options by funds: $409K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$2.75M |
| 2 |
LGM
Logos Global Management
San Francisco,
California
|
+$623K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$78.8K |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$62.6K |
| 5 |
IIA
IPG Investment Advisors
San Diego,
California
|
+$60.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citigroup
New York
|
-$2.71M |
| 2 |
BlackRock
New York
|
-$1.35M |
| 3 |
PA
Perceptive Advisors
New York
|
-$109K |
| 4 |
IWM
IHT Wealth Management
Chicago,
Illinois
|
-$102K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$56.1K |
VRNA Hedge Fund Activity: Q4 2021 in Review
42 of the 6,491 institutional investors tracked by Wall St. Rank reported a position in Verona Pharma (VRNA) for Q4 2021, worth a combined $248M — up 22% from $203M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new VRNA positions and 7 closed out — a net gain of 2 holders — while 6 added to existing stakes and 8 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $2.75M. The largest seller was Citigroup, exiting entirely with an estimated $2.71M sold.
- 42 institutional investors held Verona Pharma (VRNA) as of Q4 2021, up from 40 in Q3 2021.
- Funds reported $248M of Verona Pharma stock for Q4 2021, up 22% quarter-over-quarter.
- 9 funds opened new Verona Pharma positions in Q4 2021 and 7 closed out, a net change of +2 holders.
- The largest Verona Pharma buyer in Q4 2021 was Wellington Management Group, an estimated $2.75M added.
- The largest Verona Pharma seller in Q4 2021 was Citigroup, an estimated $2.71M sold.
Based on aggregated 13F filings for Q4 2021.